Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: EUCAST changed the definition of the 'intermediate' (I) category in 2019, now defined as 'susceptible, increased exposure'. This new definition could lead to an increased prescription of antibiotics still reported as 'S', compared with those now reported as 'I'. The objective of this study was to evaluate the influence of this definition on the use of overly broad-spectrum antibiotics for the treatment of infections caused by WT .
Methods: A retrospective observational multicentre study was conducted, involving five hospitals. Two 15 month study periods were defined, before and after the implementation of the new definition. All patients with an infection caused by WT treated by β-lactams were included. The main endpoint was the proportion of patients treated by an overly broad-spectrum antibiotic treatment by meropenem or ceftolozane/tazobactam.
Results: Two hundred and ninety-one patients were included. No difference between groups was found, in terms of infection, microbiology or demographic characteristics. Two overly broad-spectrum antibiotic treatments by meropenem or ceftolozane/tazobactam were observed in Period 1 (1.2%), versus 13 in Period 2 (10.8%; < 0.001). No overly broad-spectrum treatment was observed when the antimicrobial stewardship team had given advice.
Conclusions: This new definition can cause a negative impact on the use of overly broad-spectrum antibiotic treatment due to misunderstanding by clinicians. Its successful implementation requires adaptation of software for reporting antibiotic susceptibility, a sustained strong information campaign by microbiologists and support by an antimicrobial stewardship team.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573807 | PMC |
| http://dx.doi.org/10.1093/jacamr/dlac099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of an antimicrobial stewardship program in four district hospitals in Vietnam.
J Infect Public Health
September 2025
Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Woolcock Institute of Medical Research, Macquarie Park, Sydney, Australia.
Background: Excessive and improper use of antimicrobials is a major driver of antimicrobial resistance. Antimicrobial stewardship (AMS) addresses this by promoting judicious use of antimicrobials. This study evaluated the feasibility and effectiveness of an AMS program in district hospitals in Vietnam.
View Article and Find Full Text PDFCanadian Antibiotic Prescribing for Sepsis (CAPS) Study: A Analysis of the FABLED Cohort Study.
J Assoc Med Microbiol Infect Dis Can
December 2024
Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
Background: Understanding the microbiology and optimal pharmacotherapy of patients with community-onset sepsis is key to improving outcomes. Yet, empiric therapies prescribed in Canadian emergency departments as they relate to microbial etiology and focus of infection are inadequately described.
Methods: We performed a analysis of the FABLED cohort study, which quantified the effect of antimicrobials on blood culture yield in septic patients.
Metrics Selection and Risk Adjustment Methods to Benchmark Inpatient Antibiotic Use.
JAMA Netw Open
June 2025
Center for Access and Delivery Research and Evaluation, Iowa City Veterans Affairs (VA) Health Care System, Iowa City.
Importance: The Centers for Disease Control and Prevention offers a standardized antimicrobial administration ratio (SAAR) as an evaluation metric for inpatient antibiotic use through rankings and peer comparisons (ie, benchmarking). However, the SAAR model only accounts for facility- and unit-level factors without considering the hierarchical nature of the health care data, and it does not directly reflect patient-level factors or stewardship efforts to avoid overly broad-spectrum therapy.
Objective: To examine the use of antimicrobial use risk adjustment methods and choice of basic metrics (eg, days of therapy [DOT] and days of antimicrobial spectrum coverage [DASC], which do not and do consider antimicrobial spectrum, respectively) in hospital benchmarking.
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions.
Br J Dermatol
July 2025
Department of Dermatology, Rouen University Hospital, Normandie University and INSERM U1234, European Reference Network for Rare Skin Diseases (ERN SKIN), Centre de Référence National des Maladies Bulleuses Auto-Immunes, Rouen, France.
Background: Pemphigus is an autoimmune bullous disease (AIBD) and has two main subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). For adequate interpretation and comparison of clinical studies in pemphigus, it is essential to have outcomes and outcome measurement instruments (OMIs) that are well-defined, uniform and relevant.
Objectives: To provide a comprehensive overview of previously reported outcomes and OMIs in pemphigus clinical research over the past two decades.
Frequency of Antibiotic Overtreatment and Associated Harms in Patients Presenting With Suspected Sepsis to the Emergency Department: A Retrospective Cohort Study.
Clin Infect Dis
July 2025
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Background: Treatment guidelines recommend rapidly treating all patients with suspected sepsis with broad-spectrum antibiotics. This may contribute to antibiotic overuse. We quantified the incidence of antibiotic overtreatment and possible antibiotic-associated harms among patients with suspected sepsis.
View Article and Find Full Text PDF